nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—CYP3A4—prostate cancer	0.169	1	CbGaD
Bosentan—ABCB11—Ethinyl Estradiol—prostate cancer	0.113	0.239	CbGbCtD
Bosentan—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0414	0.0875	CbGbCtD
Bosentan—CYP2C9—Bicalutamide—prostate cancer	0.0374	0.0791	CbGbCtD
Bosentan—CYP2C9—Nilutamide—prostate cancer	0.0374	0.0791	CbGbCtD
Bosentan—ABCB11—Doxorubicin—prostate cancer	0.0325	0.0686	CbGbCtD
Bosentan—CYP2C9—Estrone—prostate cancer	0.0224	0.0474	CbGbCtD
Bosentan—CYP3A4—Bicalutamide—prostate cancer	0.0218	0.046	CbGbCtD
Bosentan—CYP3A4—Estramustine—prostate cancer	0.0202	0.0428	CbGbCtD
Bosentan—CYP3A4—Abiraterone—prostate cancer	0.018	0.0381	CbGbCtD
Bosentan—CYP3A4—Flutamide—prostate cancer	0.018	0.0381	CbGbCtD
Bosentan—CYP2C9—Capecitabine—prostate cancer	0.017	0.0359	CbGbCtD
Bosentan—CYP3A4—Cabazitaxel—prostate cancer	0.0133	0.0282	CbGbCtD
Bosentan—CYP3A4—Estrone—prostate cancer	0.013	0.0275	CbGbCtD
Bosentan—CYP2C9—Estradiol—prostate cancer	0.0129	0.0272	CbGbCtD
Bosentan—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0116	0.0246	CbGbCtD
Bosentan—CYP3A4—Conjugated Estrogens—prostate cancer	0.00853	0.018	CbGbCtD
Bosentan—CYP3A4—Mitoxantrone—prostate cancer	0.00776	0.0164	CbGbCtD
Bosentan—CYP3A4—Estradiol—prostate cancer	0.00749	0.0158	CbGbCtD
Bosentan—CYP3A4—Prednisone—prostate cancer	0.00644	0.0136	CbGbCtD
Bosentan—CYP3A4—Etoposide—prostate cancer	0.00489	0.0103	CbGbCtD
Bosentan—CYP3A4—Docetaxel—prostate cancer	0.00447	0.00945	CbGbCtD
Bosentan—EDNRB—prostate gland—prostate cancer	0.00371	0.143	CbGeAlD
Bosentan—CYP3A4—Doxorubicin—prostate cancer	0.00334	0.00705	CbGbCtD
Bosentan—EDNRA—prostate gland—prostate cancer	0.00307	0.118	CbGeAlD
Bosentan—CYP2C9—urine—prostate cancer	0.00283	0.109	CbGeAlD
Bosentan—EDNRA—seminal vesicle—prostate cancer	0.00259	0.1	CbGeAlD
Bosentan—EDNRB—urethra—prostate cancer	0.00248	0.096	CbGeAlD
Bosentan—CYP3A4—urine—prostate cancer	0.00216	0.0833	CbGeAlD
Bosentan—EDNRA—urethra—prostate cancer	0.00205	0.0793	CbGeAlD
Bosentan—EDNRB—testis—prostate cancer	0.00163	0.0631	CbGeAlD
Bosentan—EDNRA—testis—prostate cancer	0.00135	0.0522	CbGeAlD
Bosentan—ABCB11—testis—prostate cancer	0.00132	0.051	CbGeAlD
Bosentan—EDNRB—lymph node—prostate cancer	0.00118	0.0458	CbGeAlD
Bosentan—EDNRA—lymph node—prostate cancer	0.000979	0.0378	CbGeAlD
Bosentan—CYP3A4—renal system—prostate cancer	0.000527	0.0204	CbGeAlD
Bosentan—Hypoaesthesia—Epirubicin—prostate cancer	4.32e-05	0.000199	CcSEcCtD
Bosentan—Skin disorder—Capecitabine—prostate cancer	4.3e-05	0.000198	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—prostate cancer	4.29e-05	0.000198	CcSEcCtD
Bosentan—Hyperhidrosis—Capecitabine—prostate cancer	4.28e-05	0.000197	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—prostate cancer	4.28e-05	0.000197	CcSEcCtD
Bosentan—Hypotension—Docetaxel—prostate cancer	4.28e-05	0.000197	CcSEcCtD
Bosentan—Haematuria—Doxorubicin—prostate cancer	4.27e-05	0.000197	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—prostate cancer	4.26e-05	0.000196	CcSEcCtD
Bosentan—Loss of consciousness—Prednisone—prostate cancer	4.25e-05	0.000196	CcSEcCtD
Bosentan—Hepatobiliary disease—Doxorubicin—prostate cancer	4.24e-05	0.000195	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—prostate cancer	4.22e-05	0.000195	CcSEcCtD
Bosentan—Anorexia—Capecitabine—prostate cancer	4.22e-05	0.000195	CcSEcCtD
Bosentan—Nausea—Estradiol—prostate cancer	4.22e-05	0.000194	CcSEcCtD
Bosentan—Vomiting—Mitoxantrone—prostate cancer	4.21e-05	0.000194	CcSEcCtD
Bosentan—Sinusitis—Doxorubicin—prostate cancer	4.2e-05	0.000193	CcSEcCtD
Bosentan—Rash—Mitoxantrone—prostate cancer	4.18e-05	0.000192	CcSEcCtD
Bosentan—Dermatitis—Mitoxantrone—prostate cancer	4.17e-05	0.000192	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.17e-05	0.000192	CcSEcCtD
Bosentan—Headache—Mitoxantrone—prostate cancer	4.15e-05	0.000191	CcSEcCtD
Bosentan—Hypotension—Capecitabine—prostate cancer	4.14e-05	0.000191	CcSEcCtD
Bosentan—Insomnia—Docetaxel—prostate cancer	4.14e-05	0.000191	CcSEcCtD
Bosentan—Arthralgia—Prednisone—prostate cancer	4.12e-05	0.00019	CcSEcCtD
Bosentan—Paraesthesia—Docetaxel—prostate cancer	4.11e-05	0.000189	CcSEcCtD
Bosentan—Erythema multiforme—Epirubicin—prostate cancer	4.11e-05	0.000189	CcSEcCtD
Bosentan—Anxiety—Prednisone—prostate cancer	4.1e-05	0.000189	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—prostate cancer	4.09e-05	0.000188	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.09e-05	0.000188	CcSEcCtD
Bosentan—Dyspnoea—Docetaxel—prostate cancer	4.08e-05	0.000188	CcSEcCtD
Bosentan—Somnolence—Docetaxel—prostate cancer	4.07e-05	0.000187	CcSEcCtD
Bosentan—Discomfort—Prednisone—prostate cancer	4.07e-05	0.000187	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—prostate cancer	4.06e-05	0.000187	CcSEcCtD
Bosentan—Hypersensitivity—Etoposide—prostate cancer	4.06e-05	0.000187	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—prostate cancer	4.05e-05	0.000187	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—prostate cancer	4.04e-05	0.000186	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.04e-05	0.000186	CcSEcCtD
Bosentan—Flushing—Epirubicin—prostate cancer	4.03e-05	0.000186	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—prostate cancer	4.03e-05	0.000186	CcSEcCtD
Bosentan—Dyspepsia—Docetaxel—prostate cancer	4.03e-05	0.000186	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—prostate cancer	4.02e-05	0.000185	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—prostate cancer	4.02e-05	0.000185	CcSEcCtD
Bosentan—Insomnia—Capecitabine—prostate cancer	4.01e-05	0.000185	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—prostate cancer	4e-05	0.000184	CcSEcCtD
Bosentan—Paraesthesia—Capecitabine—prostate cancer	3.98e-05	0.000183	CcSEcCtD
Bosentan—Decreased appetite—Docetaxel—prostate cancer	3.98e-05	0.000183	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—prostate cancer	3.97e-05	0.000183	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—prostate cancer	3.96e-05	0.000182	CcSEcCtD
Bosentan—Gastrointestinal disorder—Docetaxel—prostate cancer	3.95e-05	0.000182	CcSEcCtD
Bosentan—Asthenia—Etoposide—prostate cancer	3.95e-05	0.000182	CcSEcCtD
Bosentan—Dyspnoea—Capecitabine—prostate cancer	3.95e-05	0.000182	CcSEcCtD
Bosentan—Oedema—Prednisone—prostate cancer	3.95e-05	0.000182	CcSEcCtD
Bosentan—Anaphylactic shock—Prednisone—prostate cancer	3.95e-05	0.000182	CcSEcCtD
Bosentan—Fatigue—Docetaxel—prostate cancer	3.95e-05	0.000182	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—prostate cancer	3.94e-05	0.000182	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—prostate cancer	3.94e-05	0.000181	CcSEcCtD
Bosentan—Nausea—Mitoxantrone—prostate cancer	3.93e-05	0.000181	CcSEcCtD
Bosentan—Immune system disorder—Epirubicin—prostate cancer	3.93e-05	0.000181	CcSEcCtD
Bosentan—Infection—Prednisone—prostate cancer	3.92e-05	0.000181	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—prostate cancer	3.92e-05	0.00018	CcSEcCtD
Bosentan—Pain—Docetaxel—prostate cancer	3.91e-05	0.00018	CcSEcCtD
Bosentan—Constipation—Docetaxel—prostate cancer	3.91e-05	0.00018	CcSEcCtD
Bosentan—Dyspepsia—Capecitabine—prostate cancer	3.9e-05	0.00018	CcSEcCtD
Bosentan—Chills—Epirubicin—prostate cancer	3.9e-05	0.00018	CcSEcCtD
Bosentan—Pruritus—Etoposide—prostate cancer	3.9e-05	0.000179	CcSEcCtD
Bosentan—Shock—Prednisone—prostate cancer	3.88e-05	0.000179	CcSEcCtD
Bosentan—Nervous system disorder—Prednisone—prostate cancer	3.87e-05	0.000178	CcSEcCtD
Bosentan—Tachycardia—Prednisone—prostate cancer	3.85e-05	0.000177	CcSEcCtD
Bosentan—Decreased appetite—Capecitabine—prostate cancer	3.85e-05	0.000177	CcSEcCtD
Bosentan—Skin disorder—Prednisone—prostate cancer	3.83e-05	0.000177	CcSEcCtD
Bosentan—Gastrointestinal disorder—Capecitabine—prostate cancer	3.83e-05	0.000176	CcSEcCtD
Bosentan—Fatigue—Capecitabine—prostate cancer	3.82e-05	0.000176	CcSEcCtD
Bosentan—Hyperhidrosis—Prednisone—prostate cancer	3.82e-05	0.000176	CcSEcCtD
Bosentan—Mental disorder—Epirubicin—prostate cancer	3.81e-05	0.000175	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—prostate cancer	3.8e-05	0.000175	CcSEcCtD
Bosentan—Pain—Capecitabine—prostate cancer	3.79e-05	0.000175	CcSEcCtD
Bosentan—Constipation—Capecitabine—prostate cancer	3.79e-05	0.000175	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—prostate cancer	3.78e-05	0.000174	CcSEcCtD
Bosentan—Erythema—Epirubicin—prostate cancer	3.78e-05	0.000174	CcSEcCtD
Bosentan—Diarrhoea—Etoposide—prostate cancer	3.77e-05	0.000174	CcSEcCtD
Bosentan—Anorexia—Prednisone—prostate cancer	3.76e-05	0.000173	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—prostate cancer	3.76e-05	0.000173	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—prostate cancer	3.75e-05	0.000173	CcSEcCtD
Bosentan—Gastrointestinal pain—Docetaxel—prostate cancer	3.74e-05	0.000172	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—prostate cancer	3.73e-05	0.000172	CcSEcCtD
Bosentan—Flushing—Doxorubicin—prostate cancer	3.73e-05	0.000172	CcSEcCtD
Bosentan—Flatulence—Epirubicin—prostate cancer	3.73e-05	0.000172	CcSEcCtD
Bosentan—Back pain—Epirubicin—prostate cancer	3.66e-05	0.000168	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—prostate cancer	3.65e-05	0.000168	CcSEcCtD
Bosentan—Dizziness—Etoposide—prostate cancer	3.64e-05	0.000168	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—prostate cancer	3.64e-05	0.000167	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—prostate cancer	3.63e-05	0.000167	CcSEcCtD
Bosentan—Gastrointestinal pain—Capecitabine—prostate cancer	3.62e-05	0.000167	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—prostate cancer	3.62e-05	0.000167	CcSEcCtD
Bosentan—Abdominal pain—Docetaxel—prostate cancer	3.62e-05	0.000167	CcSEcCtD
Bosentan—Body temperature increased—Docetaxel—prostate cancer	3.62e-05	0.000167	CcSEcCtD
Bosentan—Chills—Doxorubicin—prostate cancer	3.61e-05	0.000166	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Prednisone—prostate cancer	3.6e-05	0.000166	CcSEcCtD
Bosentan—Insomnia—Prednisone—prostate cancer	3.57e-05	0.000164	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—prostate cancer	3.57e-05	0.000164	CcSEcCtD
Bosentan—Paraesthesia—Prednisone—prostate cancer	3.54e-05	0.000163	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—prostate cancer	3.52e-05	0.000162	CcSEcCtD
Bosentan—Urticaria—Capecitabine—prostate cancer	3.52e-05	0.000162	CcSEcCtD
Bosentan—Abdominal pain—Capecitabine—prostate cancer	3.5e-05	0.000161	CcSEcCtD
Bosentan—Body temperature increased—Capecitabine—prostate cancer	3.5e-05	0.000161	CcSEcCtD
Bosentan—Vomiting—Etoposide—prostate cancer	3.5e-05	0.000161	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—prostate cancer	3.5e-05	0.000161	CcSEcCtD
Bosentan—Erythema—Doxorubicin—prostate cancer	3.5e-05	0.000161	CcSEcCtD
Bosentan—Anaemia—Epirubicin—prostate cancer	3.5e-05	0.000161	CcSEcCtD
Bosentan—Dyspepsia—Prednisone—prostate cancer	3.47e-05	0.00016	CcSEcCtD
Bosentan—Rash—Etoposide—prostate cancer	3.47e-05	0.00016	CcSEcCtD
Bosentan—Dermatitis—Etoposide—prostate cancer	3.47e-05	0.00016	CcSEcCtD
Bosentan—Headache—Etoposide—prostate cancer	3.45e-05	0.000159	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—prostate cancer	3.45e-05	0.000159	CcSEcCtD
Bosentan—Decreased appetite—Prednisone—prostate cancer	3.43e-05	0.000158	CcSEcCtD
Bosentan—Fatigue—Prednisone—prostate cancer	3.4e-05	0.000157	CcSEcCtD
Bosentan—Vertigo—Epirubicin—prostate cancer	3.4e-05	0.000156	CcSEcCtD
Bosentan—Syncope—Epirubicin—prostate cancer	3.39e-05	0.000156	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—prostate cancer	3.39e-05	0.000156	CcSEcCtD
Bosentan—Back pain—Doxorubicin—prostate cancer	3.39e-05	0.000156	CcSEcCtD
Bosentan—Constipation—Prednisone—prostate cancer	3.38e-05	0.000155	CcSEcCtD
Bosentan—Hypersensitivity—Docetaxel—prostate cancer	3.37e-05	0.000155	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—prostate cancer	3.37e-05	0.000155	CcSEcCtD
Bosentan—Palpitations—Epirubicin—prostate cancer	3.34e-05	0.000154	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—prostate cancer	3.33e-05	0.000153	CcSEcCtD
Bosentan—Cough—Epirubicin—prostate cancer	3.3e-05	0.000152	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—prostate cancer	3.3e-05	0.000152	CcSEcCtD
Bosentan—Asthenia—Docetaxel—prostate cancer	3.28e-05	0.000151	CcSEcCtD
Bosentan—Nausea—Etoposide—prostate cancer	3.27e-05	0.000151	CcSEcCtD
Bosentan—Hypersensitivity—Capecitabine—prostate cancer	3.27e-05	0.00015	CcSEcCtD
Bosentan—Pruritus—Docetaxel—prostate cancer	3.24e-05	0.000149	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—prostate cancer	3.24e-05	0.000149	CcSEcCtD
Bosentan—Gastrointestinal pain—Prednisone—prostate cancer	3.23e-05	0.000149	CcSEcCtD
Bosentan—Chest pain—Epirubicin—prostate cancer	3.22e-05	0.000148	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—prostate cancer	3.22e-05	0.000148	CcSEcCtD
Bosentan—Anxiety—Epirubicin—prostate cancer	3.21e-05	0.000148	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.2e-05	0.000147	CcSEcCtD
Bosentan—Discomfort—Epirubicin—prostate cancer	3.18e-05	0.000147	CcSEcCtD
Bosentan—Asthenia—Capecitabine—prostate cancer	3.18e-05	0.000146	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—prostate cancer	3.15e-05	0.000145	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—prostate cancer	3.14e-05	0.000145	CcSEcCtD
Bosentan—Syncope—Doxorubicin—prostate cancer	3.14e-05	0.000145	CcSEcCtD
Bosentan—Urticaria—Prednisone—prostate cancer	3.14e-05	0.000144	CcSEcCtD
Bosentan—Pruritus—Capecitabine—prostate cancer	3.14e-05	0.000144	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—prostate cancer	3.13e-05	0.000144	CcSEcCtD
Bosentan—Diarrhoea—Docetaxel—prostate cancer	3.13e-05	0.000144	CcSEcCtD
Bosentan—Body temperature increased—Prednisone—prostate cancer	3.12e-05	0.000144	CcSEcCtD
Bosentan—Abdominal pain—Prednisone—prostate cancer	3.12e-05	0.000144	CcSEcCtD
Bosentan—Palpitations—Doxorubicin—prostate cancer	3.09e-05	0.000142	CcSEcCtD
Bosentan—Oedema—Epirubicin—prostate cancer	3.09e-05	0.000142	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—prostate cancer	3.09e-05	0.000142	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—prostate cancer	3.08e-05	0.000142	CcSEcCtD
Bosentan—Infection—Epirubicin—prostate cancer	3.07e-05	0.000141	CcSEcCtD
Bosentan—Cough—Doxorubicin—prostate cancer	3.05e-05	0.000141	CcSEcCtD
Bosentan—Shock—Epirubicin—prostate cancer	3.04e-05	0.00014	CcSEcCtD
Bosentan—Diarrhoea—Capecitabine—prostate cancer	3.03e-05	0.00014	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—prostate cancer	3.03e-05	0.000139	CcSEcCtD
Bosentan—Dizziness—Docetaxel—prostate cancer	3.03e-05	0.000139	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—prostate cancer	3.02e-05	0.000139	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—prostate cancer	3.01e-05	0.000139	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—prostate cancer	3e-05	0.000138	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—prostate cancer	2.98e-05	0.000137	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—prostate cancer	2.98e-05	0.000137	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—prostate cancer	2.98e-05	0.000137	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—prostate cancer	2.97e-05	0.000137	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.96e-05	0.000136	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—prostate cancer	2.94e-05	0.000136	CcSEcCtD
Bosentan—Anorexia—Epirubicin—prostate cancer	2.94e-05	0.000136	CcSEcCtD
Bosentan—Dizziness—Capecitabine—prostate cancer	2.93e-05	0.000135	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—prostate cancer	2.91e-05	0.000134	CcSEcCtD
Bosentan—Vomiting—Docetaxel—prostate cancer	2.91e-05	0.000134	CcSEcCtD
Bosentan—Hypersensitivity—Prednisone—prostate cancer	2.91e-05	0.000134	CcSEcCtD
Bosentan—Rash—Docetaxel—prostate cancer	2.89e-05	0.000133	CcSEcCtD
Bosentan—Hypotension—Epirubicin—prostate cancer	2.89e-05	0.000133	CcSEcCtD
Bosentan—Dermatitis—Docetaxel—prostate cancer	2.88e-05	0.000133	CcSEcCtD
Bosentan—Headache—Docetaxel—prostate cancer	2.87e-05	0.000132	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—prostate cancer	2.86e-05	0.000132	CcSEcCtD
Bosentan—Oedema—Doxorubicin—prostate cancer	2.86e-05	0.000132	CcSEcCtD
Bosentan—Infection—Doxorubicin—prostate cancer	2.84e-05	0.000131	CcSEcCtD
Bosentan—Asthenia—Prednisone—prostate cancer	2.83e-05	0.00013	CcSEcCtD
Bosentan—Vomiting—Capecitabine—prostate cancer	2.82e-05	0.00013	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.81e-05	0.00013	CcSEcCtD
Bosentan—Shock—Doxorubicin—prostate cancer	2.81e-05	0.000129	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—prostate cancer	2.8e-05	0.000129	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—prostate cancer	2.8e-05	0.000129	CcSEcCtD
Bosentan—Rash—Capecitabine—prostate cancer	2.79e-05	0.000129	CcSEcCtD
Bosentan—Pruritus—Prednisone—prostate cancer	2.79e-05	0.000129	CcSEcCtD
Bosentan—Insomnia—Epirubicin—prostate cancer	2.79e-05	0.000129	CcSEcCtD
Bosentan—Dermatitis—Capecitabine—prostate cancer	2.79e-05	0.000129	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—prostate cancer	2.79e-05	0.000128	CcSEcCtD
Bosentan—Headache—Capecitabine—prostate cancer	2.78e-05	0.000128	CcSEcCtD
Bosentan—Skin disorder—Doxorubicin—prostate cancer	2.77e-05	0.000128	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—prostate cancer	2.77e-05	0.000128	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—prostate cancer	2.76e-05	0.000127	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—prostate cancer	2.75e-05	0.000127	CcSEcCtD
Bosentan—Somnolence—Epirubicin—prostate cancer	2.74e-05	0.000126	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—prostate cancer	2.72e-05	0.000125	CcSEcCtD
Bosentan—Nausea—Docetaxel—prostate cancer	2.72e-05	0.000125	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—prostate cancer	2.72e-05	0.000125	CcSEcCtD
Bosentan—Diarrhoea—Prednisone—prostate cancer	2.7e-05	0.000124	CcSEcCtD
Bosentan—Decreased appetite—Epirubicin—prostate cancer	2.68e-05	0.000124	CcSEcCtD
Bosentan—Hypotension—Doxorubicin—prostate cancer	2.67e-05	0.000123	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—prostate cancer	2.67e-05	0.000123	CcSEcCtD
Bosentan—Fatigue—Epirubicin—prostate cancer	2.66e-05	0.000123	CcSEcCtD
Bosentan—Constipation—Epirubicin—prostate cancer	2.64e-05	0.000122	CcSEcCtD
Bosentan—Pain—Epirubicin—prostate cancer	2.64e-05	0.000122	CcSEcCtD
Bosentan—Nausea—Capecitabine—prostate cancer	2.63e-05	0.000121	CcSEcCtD
Bosentan—Dizziness—Prednisone—prostate cancer	2.61e-05	0.00012	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.6e-05	0.00012	CcSEcCtD
Bosentan—Insomnia—Doxorubicin—prostate cancer	2.58e-05	0.000119	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—prostate cancer	2.57e-05	0.000118	CcSEcCtD
Bosentan—Dyspnoea—Doxorubicin—prostate cancer	2.55e-05	0.000117	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—prostate cancer	2.54e-05	0.000117	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—prostate cancer	2.52e-05	0.000116	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—prostate cancer	2.51e-05	0.000116	CcSEcCtD
Bosentan—Vomiting—Prednisone—prostate cancer	2.51e-05	0.000116	CcSEcCtD
Bosentan—Rash—Prednisone—prostate cancer	2.49e-05	0.000115	CcSEcCtD
Bosentan—Dermatitis—Prednisone—prostate cancer	2.49e-05	0.000115	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—prostate cancer	2.48e-05	0.000114	CcSEcCtD
Bosentan—Headache—Prednisone—prostate cancer	2.47e-05	0.000114	CcSEcCtD
Bosentan—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.47e-05	0.000114	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—prostate cancer	2.46e-05	0.000113	CcSEcCtD
Bosentan—Urticaria—Epirubicin—prostate cancer	2.45e-05	0.000113	CcSEcCtD
Bosentan—Constipation—Doxorubicin—prostate cancer	2.44e-05	0.000112	CcSEcCtD
Bosentan—Pain—Doxorubicin—prostate cancer	2.44e-05	0.000112	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—prostate cancer	2.44e-05	0.000112	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—prostate cancer	2.44e-05	0.000112	CcSEcCtD
Bosentan—Nausea—Prednisone—prostate cancer	2.34e-05	0.000108	CcSEcCtD
Bosentan—Gastrointestinal pain—Doxorubicin—prostate cancer	2.34e-05	0.000108	CcSEcCtD
Bosentan—Hypersensitivity—Epirubicin—prostate cancer	2.27e-05	0.000105	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—prostate cancer	2.27e-05	0.000104	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—prostate cancer	2.26e-05	0.000104	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—prostate cancer	2.26e-05	0.000104	CcSEcCtD
Bosentan—Asthenia—Epirubicin—prostate cancer	2.22e-05	0.000102	CcSEcCtD
Bosentan—Pruritus—Epirubicin—prostate cancer	2.18e-05	0.000101	CcSEcCtD
Bosentan—Diarrhoea—Epirubicin—prostate cancer	2.11e-05	9.73e-05	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—prostate cancer	2.1e-05	9.69e-05	CcSEcCtD
Bosentan—Asthenia—Doxorubicin—prostate cancer	2.05e-05	9.44e-05	CcSEcCtD
Bosentan—Dizziness—Epirubicin—prostate cancer	2.04e-05	9.4e-05	CcSEcCtD
Bosentan—Pruritus—Doxorubicin—prostate cancer	2.02e-05	9.31e-05	CcSEcCtD
Bosentan—Vomiting—Epirubicin—prostate cancer	1.96e-05	9.04e-05	CcSEcCtD
Bosentan—Diarrhoea—Doxorubicin—prostate cancer	1.95e-05	9e-05	CcSEcCtD
Bosentan—Rash—Epirubicin—prostate cancer	1.95e-05	8.96e-05	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—prostate cancer	1.94e-05	8.96e-05	CcSEcCtD
Bosentan—Headache—Epirubicin—prostate cancer	1.93e-05	8.91e-05	CcSEcCtD
Bosentan—Dizziness—Doxorubicin—prostate cancer	1.89e-05	8.7e-05	CcSEcCtD
Bosentan—Nausea—Epirubicin—prostate cancer	1.83e-05	8.44e-05	CcSEcCtD
Bosentan—Vomiting—Doxorubicin—prostate cancer	1.82e-05	8.36e-05	CcSEcCtD
Bosentan—Rash—Doxorubicin—prostate cancer	1.8e-05	8.29e-05	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—prostate cancer	1.8e-05	8.29e-05	CcSEcCtD
Bosentan—Headache—Doxorubicin—prostate cancer	1.79e-05	8.24e-05	CcSEcCtD
Bosentan—Nausea—Doxorubicin—prostate cancer	1.7e-05	7.81e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—INS—prostate cancer	1.03e-05	8.97e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	1.03e-05	8.94e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—prostate cancer	1.02e-05	8.82e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1.01e-05	8.8e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1A—prostate cancer	1.01e-05	8.79e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CREBBP—prostate cancer	1.01e-05	8.79e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ACSL4—prostate cancer	1.01e-05	8.78e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HSD17B3—prostate cancer	1.01e-05	8.78e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—prostate cancer	1.01e-05	8.77e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MTHFR—prostate cancer	1e-05	8.7e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1—prostate cancer	9.99e-06	8.68e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	9.99e-06	8.68e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—prostate cancer	9.94e-06	8.64e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—prostate cancer	9.85e-06	8.56e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PPARA—prostate cancer	9.82e-06	8.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AOX1—prostate cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—RFK—prostate cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTM3—prostate cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MBTPS1—prostate cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NAGLU—prostate cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SULT2B1—prostate cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PGAM2—prostate cancer	9.72e-06	8.45e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—UMPS—prostate cancer	9.69e-06	8.41e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ARG2—prostate cancer	9.69e-06	8.41e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PHGDH—prostate cancer	9.69e-06	8.41e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAP2K1—prostate cancer	9.66e-06	8.39e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	9.64e-06	8.37e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EP300—prostate cancer	9.63e-06	8.36e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CD—prostate cancer	9.59e-06	8.33e-05	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—prostate cancer	9.5e-06	8.26e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—LDHB—prostate cancer	9.5e-06	8.25e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SERPINE1—prostate cancer	9.49e-06	8.24e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—prostate cancer	9.39e-06	8.16e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SRC—prostate cancer	9.36e-06	8.13e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP3A5—prostate cancer	9.32e-06	8.1e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CAV1—prostate cancer	9.23e-06	8.02e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP3A43—prostate cancer	9.22e-06	8.01e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AMACR—prostate cancer	9.22e-06	8.01e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DEGS1—prostate cancer	9.22e-06	8.01e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SRD5A2—prostate cancer	9.22e-06	8.01e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NAT1—prostate cancer	9.22e-06	8.01e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGF2—prostate cancer	9.19e-06	7.98e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—prostate cancer	9.12e-06	7.92e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOS3—prostate cancer	9.06e-06	7.87e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STAT3—prostate cancer	9.03e-06	7.84e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PDHA1—prostate cancer	9e-06	7.82e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—UCP3—prostate cancer	9e-06	7.82e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA3—prostate cancer	9e-06	7.82e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TCN2—prostate cancer	9e-06	7.82e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.82e-06	7.66e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JAK2—prostate cancer	8.8e-06	7.65e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSD17B1—prostate cancer	8.79e-06	7.64e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—prostate cancer	8.63e-06	7.5e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MDM2—prostate cancer	8.59e-06	7.47e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HSD3B1—prostate cancer	8.59e-06	7.46e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC22A3—prostate cancer	8.59e-06	7.46e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—prostate cancer	8.47e-06	7.36e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CG—prostate cancer	8.41e-06	7.31e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—prostate cancer	8.39e-06	7.29e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFB1—prostate cancer	8.37e-06	7.27e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CB—prostate cancer	8.36e-06	7.26e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	8.33e-06	7.24e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TBXAS1—prostate cancer	8.24e-06	7.15e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA4—prostate cancer	8.24e-06	7.15e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—prostate cancer	8.21e-06	7.13e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	8.05e-06	6.99e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL8—prostate cancer	8.04e-06	6.98e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA2—prostate cancer	8.03e-06	6.97e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—INS—prostate cancer	7.96e-06	6.92e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SULT1A1—prostate cancer	7.93e-06	6.89e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCG5—prostate cancer	7.93e-06	6.89e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1B—prostate cancer	7.85e-06	6.82e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HPGD—prostate cancer	7.84e-06	6.81e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—B4GALT4—prostate cancer	7.84e-06	6.81e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CREBBP—prostate cancer	7.8e-06	6.77e-05	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—prostate cancer	7.76e-06	6.74e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—prostate cancer	7.75e-06	6.74e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA1—prostate cancer	7.74e-06	6.73e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP3—prostate cancer	7.69e-06	6.68e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—prostate cancer	7.68e-06	6.67e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTO1—prostate cancer	7.66e-06	6.65e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HSD3B2—prostate cancer	7.66e-06	6.65e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NAT2—prostate cancer	7.66e-06	6.65e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6—prostate cancer	7.64e-06	6.64e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—prostate cancer	7.49e-06	6.5e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CTNNB1—prostate cancer	7.41e-06	6.44e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CD—prostate cancer	7.39e-06	6.42e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TNFRSF21—prostate cancer	7.37e-06	6.4e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	7.36e-06	6.4e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PLCB2—prostate cancer	7.34e-06	6.38e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP2C18—prostate cancer	7.34e-06	6.38e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—LRP2—prostate cancer	7.34e-06	6.38e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—prostate cancer	7.27e-06	6.31e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1A—prostate cancer	7.24e-06	6.29e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—prostate cancer	7.23e-06	6.28e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—P4HB—prostate cancer	7.2e-06	6.25e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP7B1—prostate cancer	7.17e-06	6.23e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTAP—prostate cancer	7.17e-06	6.23e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—prostate cancer	7.12e-06	6.19e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—prostate cancer	7.05e-06	6.12e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC22A1—prostate cancer	7e-06	6.08e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SULT1E1—prostate cancer	6.98e-06	6.07e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SRD5A1—prostate cancer	6.98e-06	6.07e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NOS3—prostate cancer	6.98e-06	6.07e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	6.92e-06	6.01e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EP300—prostate cancer	6.89e-06	5.99e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—prostate cancer	6.89e-06	5.99e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SULT2A1—prostate cancer	6.82e-06	5.93e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MED12—prostate cancer	6.71e-06	5.83e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SRC—prostate cancer	6.7e-06	5.82e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSD17B3—prostate cancer	6.66e-06	5.79e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ACSL4—prostate cancer	6.66e-06	5.79e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GNG5—prostate cancer	6.66e-06	5.79e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—prostate cancer	6.53e-06	5.67e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT3—prostate cancer	6.46e-06	5.61e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CB—prostate cancer	6.44e-06	5.6e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOA3—prostate cancer	6.42e-06	5.57e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—UMPS—prostate cancer	6.39e-06	5.55e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PHGDH—prostate cancer	6.39e-06	5.55e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ARG2—prostate cancer	6.39e-06	5.55e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—prostate cancer	6.39e-06	5.55e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6—prostate cancer	6.31e-06	5.48e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.3e-06	5.48e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—LDHB—prostate cancer	6.26e-06	5.44e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP3A5—prostate cancer	6.15e-06	5.34e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HPGDS—prostate cancer	6.12e-06	5.32e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP2C19—prostate cancer	6.08e-06	5.28e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—prostate cancer	6e-06	5.22e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFB1—prostate cancer	5.99e-06	5.2e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PDHA1—prostate cancer	5.94e-06	5.16e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TCN2—prostate cancer	5.94e-06	5.16e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA3—prostate cancer	5.94e-06	5.16e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—UCP3—prostate cancer	5.94e-06	5.16e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTT1—prostate cancer	5.94e-06	5.16e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ACHE—prostate cancer	5.94e-06	5.16e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—prostate cancer	5.87e-06	5.1e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP2A6—prostate cancer	5.87e-06	5.1e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.85e-06	5.08e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—prostate cancer	5.82e-06	5.05e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKR1C3—prostate cancer	5.71e-06	4.96e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PRKACB—prostate cancer	5.68e-06	4.93e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC22A3—prostate cancer	5.67e-06	4.92e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSD3B1—prostate cancer	5.67e-06	4.92e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP17A1—prostate cancer	5.62e-06	4.88e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—prostate cancer	5.57e-06	4.84e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—prostate cancer	5.55e-06	4.82e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.54e-06	4.82e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA4—prostate cancer	5.43e-06	4.72e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TBXAS1—prostate cancer	5.43e-06	4.72e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOA2—prostate cancer	5.35e-06	4.65e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—EP300—prostate cancer	5.31e-06	4.61e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA2—prostate cancer	5.29e-06	4.6e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SULT1A1—prostate cancer	5.23e-06	4.54e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCG5—prostate cancer	5.23e-06	4.54e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC5A5—prostate cancer	5.11e-06	4.44e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA1—prostate cancer	5.11e-06	4.44e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—prostate cancer	5.1e-06	4.43e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NAT2—prostate cancer	5.05e-06	4.39e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTO1—prostate cancer	5.05e-06	4.39e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSD3B2—prostate cancer	5.05e-06	4.39e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP2E1—prostate cancer	4.99e-06	4.33e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NQO1—prostate cancer	4.93e-06	4.29e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—prostate cancer	4.93e-06	4.28e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TH—prostate cancer	4.86e-06	4.22e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PLCB2—prostate cancer	4.84e-06	4.21e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.84e-06	4.21e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—LRP2—prostate cancer	4.84e-06	4.21e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.83e-06	4.2e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP3A4—prostate cancer	4.81e-06	4.18e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.79e-06	4.16e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—P4HB—prostate cancer	4.75e-06	4.12e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1B1—prostate cancer	4.73e-06	4.11e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.62e-06	4.01e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GGT1—prostate cancer	4.58e-06	3.98e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6—prostate cancer	4.51e-06	3.92e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOA1—prostate cancer	4.51e-06	3.92e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.5e-06	3.91e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP19A1—prostate cancer	4.45e-06	3.86e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MED12—prostate cancer	4.43e-06	3.85e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GNG5—prostate cancer	4.39e-06	3.82e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—RXRA—prostate cancer	4.29e-06	3.73e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOA3—prostate cancer	4.23e-06	3.68e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.17e-06	3.63e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—prostate cancer	4.16e-06	3.62e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—COMT—prostate cancer	4.13e-06	3.59e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTP1—prostate cancer	4.12e-06	3.57e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ITPR1—prostate cancer	4.05e-06	3.52e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HPGDS—prostate cancer	4.04e-06	3.51e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.01e-06	3.48e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.98e-06	3.46e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—prostate cancer	3.93e-06	3.41e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTT1—prostate cancer	3.92e-06	3.4e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ACHE—prostate cancer	3.92e-06	3.4e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.87e-06	3.36e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMS—prostate cancer	3.83e-06	3.32e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTM1—prostate cancer	3.78e-06	3.29e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.76e-06	3.27e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PRKACB—prostate cancer	3.74e-06	3.25e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—LPL—prostate cancer	3.71e-06	3.22e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.71e-06	3.22e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1A1—prostate cancer	3.58e-06	3.11e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ERCC2—prostate cancer	3.56e-06	3.09e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOA2—prostate cancer	3.53e-06	3.07e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.37e-06	2.93e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTHFR—prostate cancer	3.34e-06	2.9e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.29e-06	2.86e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPARA—prostate cancer	3.28e-06	2.85e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NQO1—prostate cancer	3.25e-06	2.83e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—prostate cancer	3.21e-06	2.79e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TH—prostate cancer	3.21e-06	2.79e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.12e-06	2.71e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CAV1—prostate cancer	3.08e-06	2.68e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GGT1—prostate cancer	3.02e-06	2.62e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOA1—prostate cancer	2.98e-06	2.59e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.95e-06	2.56e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.93e-06	2.55e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—RXRA—prostate cancer	2.83e-06	2.46e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.81e-06	2.44e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—COMT—prostate cancer	2.73e-06	2.37e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTP1—prostate cancer	2.71e-06	2.36e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ITPR1—prostate cancer	2.67e-06	2.32e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—INS—prostate cancer	2.66e-06	2.31e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CREBBP—prostate cancer	2.6e-06	2.26e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMS—prostate cancer	2.52e-06	2.19e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTM1—prostate cancer	2.49e-06	2.17e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.47e-06	2.14e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—LPL—prostate cancer	2.45e-06	2.13e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.36e-06	2.05e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ERCC2—prostate cancer	2.34e-06	2.04e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NOS3—prostate cancer	2.33e-06	2.02e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTHFR—prostate cancer	2.2e-06	1.91e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPARA—prostate cancer	2.16e-06	1.88e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CB—prostate cancer	2.15e-06	1.87e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—prostate cancer	2.13e-06	1.85e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CAV1—prostate cancer	2.03e-06	1.77e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—prostate cancer	1.86e-06	1.62e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.85e-06	1.61e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—EP300—prostate cancer	1.77e-06	1.54e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—INS—prostate cancer	1.75e-06	1.52e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CREBBP—prostate cancer	1.72e-06	1.49e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.63e-06	1.41e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NOS3—prostate cancer	1.54e-06	1.34e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.42e-06	1.23e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—prostate cancer	1.41e-06	1.22e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.31e-06	1.14e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—prostate cancer	1.23e-06	1.07e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—EP300—prostate cancer	1.17e-06	1.02e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—prostate cancer	1.07e-06	9.31e-06	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.65e-07	7.51e-06	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—prostate cancer	7.07e-07	6.14e-06	CbGpPWpGaD
